이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

2017년 8월 15일 업데이트: National Cancer Institute (NCI)

A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors

This randomized phase III trial studies imatinib mesylate and bevacizumab to see how well they work compared to imatinib mesylate alone in treating patients with gastrointestinal stromal tumor that has spread to other parts of the body or cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether imatinib mesylate and bevacizumab are more effective than imatinib mesylate alone in treating gastrointestinal stromal tumor.

연구 개요

상태

종료됨

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVES:

I. To determine whether treatment with imatinib (imatinib mesylate) plus bevacizumab leads to improved progression free survival (PFS) versus treatment with imatinib alone in first-line treatment of incurable gastrointestinal stromal tumor (GIST).

SECONDARY OBJECTIVES:

I. To compare response probabilities (confirmed and unconfirmed complete response [CR] and partial response [PR] for subset of patients with measurable disease), overall survival, and central-review based progression-free survival (CRb-PFS) in patients treated with imatinib and bevacizumab versus those treated with imatinib alone.

II. To compare the frequency and severity of toxicities associated with imatinib plus bevacizumab versus imatinib alone.

TERTIARY OBJECTIVES:

I. To explore the association between soluble vascular endothelial growth factor (VEGF), VEGF-factor D (VEGF-D), VEGF receptor (VEGFR)-1, VEGFR-2, angiopoietin-2 (Ang-2), platelet-derived growth factor receptor (PDGFR)-AA and PDGFR-BB levels, positron emission tomography (PET) imaging and immunohistochemistry for cyclin-dependent kinase inhibitor 2A (p16), VEGF and VEGFR, with kinase mutation status and clinical outcomes.

II. To explore imatinib pharmacokinetics with single nucleotide polymorphisms involving the adenosine triphosphate (ATP)-binding cassette, sub-family G (WHITE), member 2 (ABCG2) and cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) genes, as well as other genes that are reported to influence the absorption, distribution, metabolism and elimination of imatinib.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (CLOSED TO ACCRUAL 10/1/2009): Patients receive imatinib mesylate orally (PO) once daily (QD) on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1.

ARM II (CLOSED TO ACCRUAL 10/1/2009): Patients receive imatinib mesylate PO QD on days 1-21.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 1 month, every 6 months for 2 years, and then annually for 5 years.

연구 유형

중재적

등록 (실제)

12

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • California
      • Berkeley, California, 미국, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burlingame, California, 미국, 94010
        • Mills - Peninsula Hospitals
      • Greenbrae, California, 미국, 94904
        • Marin General Hospital
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Novato, California, 미국, 94945
        • Sutter Cancer Research Consortium
      • San Francisco, California, 미국, 94118
        • California Pacific Medical Center-Pacific Campus
      • Vallejo, California, 미국, 94589
        • Sutter Solano Medical Center/Cancer Center
    • District of Columbia
      • Washington, D.C., District of Columbia, 미국, 20007
        • MedStar Georgetown University Hospital
    • Georgia
      • Columbus, Georgia, 미국, 31904
        • John B Amos Cancer Center
      • Savannah, Georgia, 미국, 31404
        • Memorial University Medical Center
      • Valdosta, Georgia, 미국, 31603
        • South Georgia Medical Center
    • Illinois
      • Aurora, Illinois, 미국, 60504
        • Rush - Copley Medical Center
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, 미국, 60631
        • Presence Resurrection Medical Center
      • Decatur, Illinois, 미국, 62526
        • Decatur Memorial Hospital
      • Joliet, Illinois, 미국, 60435
        • Joliet Oncology-Hematology Associates Limited
      • La Grange, Illinois, 미국, 60525
        • Adventist La Grange Memorial Hospital
      • Naperville, Illinois, 미국, 60540
        • Edward Hospital/Cancer Center
      • Springfield, Illinois, 미국, 62781
        • Memorial Medical Center
      • Urbana, Illinois, 미국, 61801
        • Carle Cancer Center
      • Urbana, Illinois, 미국, 61801
        • Carle Clinic-Urbana Main
    • Indiana
      • Beech Grove, Indiana, 미국, 46107
        • Franciscan St. Francis Health-Beech Grove
      • Michigan City, Indiana, 미국, 46360
        • Franciscan Saint Anthony Health-Michigan City
      • Richmond, Indiana, 미국, 47374
        • Reid Hospital and Health Care Services
    • Iowa
      • Ames, Iowa, 미국, 50010
        • McFarland Clinic PC-William R Bliss Cancer Center
      • Clive, Iowa, 미국, 50325
        • Medical Oncology and Hematology Associates-West Des Moines
      • Davenport, Iowa, 미국, 52803
        • Genesis Medical Center - East Campus
      • Davenport, Iowa, 미국, 52804
        • Genesis Medical Center - West Campus
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50309
        • Medical Oncology and Hematology Associates-Des Moines
      • Des Moines, Iowa, 미국, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, 미국, 50314
        • Medical Oncology and Hematology Associates-Laurel
      • Des Moines, Iowa, 미국, 50307
        • Mercy Capitol
      • Des Moines, Iowa, 미국, 50309
        • Iowa Oncology Research Association CCOP
      • Sioux City, Iowa, 미국, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, 미국, 51104
        • Saint Luke's Regional Medical Center
      • Sioux City, Iowa, 미국, 51104
        • Mercy Medical Center-Sioux City
    • Kansas
      • Chanute, Kansas, 미국, 66720
        • Cancer Center of Kansas - Chanute
      • Dodge City, Kansas, 미국, 67801
        • Cancer Center of Kansas - Dodge City
      • El Dorado, Kansas, 미국, 67042
        • Cancer Center of Kansas - El Dorado
      • Fort Scott, Kansas, 미국, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, 미국, 67301
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, 미국, 67068
        • Cancer Center of Kansas-Kingman
      • Lawrence, Kansas, 미국, 66044
        • Lawrence Memorial Hospital
      • Newton, Kansas, 미국, 67114
        • Cancer Center of Kansas - Newton
      • Parsons, Kansas, 미국, 67357
        • Cancer Center of Kansas - Parsons
      • Pratt, Kansas, 미국, 67124
        • Cancer Center of Kansas - Pratt
      • Salina, Kansas, 미국, 67401
        • Salina Regional Health Center
      • Salina, Kansas, 미국, 67401
        • Cancer Center of Kansas - Salina
      • Wellington, Kansas, 미국, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, 미국, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, 미국, 67208
        • Associates In Womens Health
      • Wichita, Kansas, 미국, 67214
        • Cancer Center of Kansas - Main Office
      • Wichita, Kansas, 미국, 67214
        • Via Christi Regional Medical Center
      • Wichita, Kansas, 미국, 67214
        • Wichita CCOP
      • Winfield, Kansas, 미국, 67156
        • Cancer Center of Kansas - Winfield
    • Michigan
      • Adrian, Michigan, 미국, 49221
        • Bixby Medical Center
      • Adrian, Michigan, 미국, 49221
        • Hickman Cancer Center
      • Ann Arbor, Michigan, 미국, 48106-0995
        • Saint Joseph Mercy Hospital
      • Ann Arbor, Michigan, 미국, 48106
        • Michigan Cancer Research Consortium CCOP
      • Dearborn, Michigan, 미국, 48124
        • Oakwood Hospital and Medical Center
      • Detroit, Michigan, 미국, 48236
        • Saint John Hospital and Medical Center
      • Flint, Michigan, 미국, 48502
        • Hurley Medical Center
      • Flint, Michigan, 미국, 48532
        • Genesys Regional Medical Center-West Flint Campus
      • Jackson, Michigan, 미국, 49201
        • Allegiance Health
      • Lansing, Michigan, 미국, 48912
        • Sparrow Hospital
      • Livonia, Michigan, 미국, 48154
        • Saint Mary Mercy Hospital
      • Monroe, Michigan, 미국, 48162
        • Mercy Memorial Hospital
      • Monroe, Michigan, 미국, 48162
        • Toledo Clinic Cancer Centers-Monroe
      • Pontiac, Michigan, 미국, 48341
        • Saint Joseph Mercy Oakland
      • Port Huron, Michigan, 미국, 48060
        • Saint Joseph Mercy Port Huron
      • Saginaw, Michigan, 미국, 48601
        • Saint Mary's of Michigan
      • Saint Joseph, Michigan, 미국, 49085
        • Oncology Care Associates PLLC
      • Southfield, Michigan, 미국, 48075
        • Providence Hospital-Southfield Cancer Center
      • Warren, Michigan, 미국, 48093
        • Saint John Macomb-Oakland Hospital
    • Minnesota
      • Duluth, Minnesota, 미국, 55805
        • Essentia Health Cancer Center
      • Duluth, Minnesota, 미국, 55805
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, 미국, 55805
        • Miller-Dwan Hospital
      • Hutchinson, Minnesota, 미국, 55350
        • Hutchinson Area Health Care
      • Litchfield, Minnesota, 미국, 55355
        • Meeker County Memorial Hospital
      • Maplewood, Minnesota, 미국, 55109
        • Saint John's Hospital - Healtheast
      • Minneapolis, Minnesota, 미국, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, 미국, 55407
        • Virginia Piper Cancer Institute
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, 미국, 55102
        • Saint Joseph's Hospital - Healtheast
      • Shakopee, Minnesota, 미국, 55379
        • Saint Francis Regional Medical Center
      • Woodbury, Minnesota, 미국, 55125
        • Woodwinds Health Campus
    • Missouri
      • Springfield, Missouri, 미국, 65804
        • Cancer Research for the Ozarks NCORP
      • Springfield, Missouri, 미국, 65804
        • Mercy Hospital Springfield
    • Montana
      • Billings, Montana, 미국, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, 미국, 59101
        • Northern Rockies Radiation Oncology Center
      • Billings, Montana, 미국, 59101
        • Montana Cancer Consortium CCOP
      • Billings, Montana, 미국, 59102
        • Frontier Cancer Center and Blood Institute-Billings
      • Billings, Montana, 미국, 59107
        • Billings Clinic Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Deaconess Hospital
      • Bozeman, Montana, 미국, 59715
        • Bozeman Deaconess Cancer Center
      • Butte, Montana, 미국, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, 미국, 59405
        • Great Falls Clinic
      • Great Falls, Montana, 미국, 59405
        • Berdeaux, Donald MD (UIA Investigator)
      • Havre, Montana, 미국, 59501
        • Northern Montana Hospital
      • Helena, Montana, 미국, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, 미국, 59901
        • Kalispell Regional Medical Center
      • Kalispell, Montana, 미국, 59901
        • Glacier Oncology PLLC
      • Kalispell, Montana, 미국, 59901
        • Kalispell Medical Oncology
      • Missoula, Montana, 미국, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, 미국, 59804
        • Guardian Oncology and Center for Wellness
      • Missoula, Montana, 미국, 59801
        • Community Medical Hospital
      • Missoula, Montana, 미국, 59802
        • Montana Cancer Specialists
    • New Jersey
      • Mount Holly, New Jersey, 미국, 08060
        • Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County
      • Voorhees, New Jersey, 미국, 08043
        • Virtua West Jersey Hospital Voorhees
    • New York
      • Buffalo, New York, 미국, 14263
        • Roswell Park Cancer Institute
      • Glens Falls, New York, 미국, 12801
        • Glens Falls Hospital
      • Middletown, New York, 미국, 10940
        • Orange Regional Medical Center
      • Rochester, New York, 미국, 14642
        • University of Rochester
      • Rochester, New York, 미국, 14620
        • Highland Hospital
      • Rochester, New York, 미국, 14623
        • Interlakes Foundation Inc-Rochester
    • North Carolina
      • Kinston, North Carolina, 미국, 28501
        • Kinston Medical Specialists PA
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Bismarck, North Dakota, 미국, 58501
        • Mid Dakota Clinic
      • Bismarck, North Dakota, 미국, 58501
        • Saint Alexius Medical Center
    • Ohio
      • Bowling Green, Ohio, 미국, 43402
        • Toledo Clinic Cancer Centers-Bowling Green
      • Cincinnati, Ohio, 미국, 45267
        • University of Cincinnati
      • Clyde, Ohio, 미국, 43410
        • North Coast Cancer Care-Clyde
      • Dayton, Ohio, 미국, 45406
        • Good Samaritan Hospital - Dayton
      • Dayton, Ohio, 미국, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, 미국, 45415
        • Samaritan North Health Center
      • Dayton, Ohio, 미국, 45405
        • Grandview Hospital
      • Dayton, Ohio, 미국, 45420
        • Dayton CCOP
      • Dayton, Ohio, 미국, 45428
        • Veteran Affairs Medical Center
      • Elyria, Ohio, 미국, 44035
        • Hematology Oncology Center Incorporated
      • Findlay, Ohio, 미국, 45840
        • Blanchard Valley Hospital
      • Franklin, Ohio, 미국, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Greenville, Ohio, 미국, 45331
        • Wayne Hospital
      • Kettering, Ohio, 미국, 45429
        • Kettering Medical Center
      • Lima, Ohio, 미국, 45804
        • Lima Memorial Hospital
      • Maumee, Ohio, 미국, 43537
        • Toledo Clinic Cancer Centers-Maumee
      • Maumee, Ohio, 미국, 43537
        • Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
      • Maumee, Ohio, 미국, 43537
        • Saint Luke's Hospital
      • Oregon, Ohio, 미국, 43616
        • Saint Charles Hospital
      • Oregon, Ohio, 미국, 43616
        • Toledo Clinic Cancer Centers-Oregon
      • Sandusky, Ohio, 미국, 44870
        • North Coast Cancer Care
      • Sylvania, Ohio, 미국, 43560
        • Flower Hospital
      • Tiffin, Ohio, 미국, 44883
        • Mercy Hospital of Tiffin
      • Toledo, Ohio, 미국, 43608
        • Saint Vincent Mercy Medical Center
      • Toledo, Ohio, 미국, 43623
        • Toledo Clinic Cancer Centers-Toledo
      • Toledo, Ohio, 미국, 43614
        • University of Toledo
      • Toledo, Ohio, 미국, 43617
        • Toledo Community Hospital Oncology Program CCOP
      • Toledo, Ohio, 미국, 43606
        • The Toledo Hospital/Toledo Children's Hospital
      • Toledo, Ohio, 미국, 43623
        • Mercy Saint Anne Hospital
      • Troy, Ohio, 미국, 45373
        • Upper Valley Medical Center
      • Wauseon, Ohio, 미국, 43567
        • Fulton County Health Center
      • Wilmington, Ohio, 미국, 45177
        • Clinton Memorial Hospital
      • Xenia, Ohio, 미국, 45385
        • Greene Memorial Hospital
    • Oregon
      • Portland, Oregon, 미국, 97216
        • Adventist Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19111
        • Fox Chase Cancer Center
      • Wilkes-Barre, Pennsylvania, 미국, 18765
        • Geisinger South Wilkes-Barre
    • South Dakota
      • Rapid City, South Dakota, 미국, 57701
        • Rapid City Regional Hospital
    • Texas
      • San Antonio, Texas, 미국, 78229
        • University Hospital
      • San Antonio, Texas, 미국, 78229
        • University of Texas Health Science Center at San Antonio
      • San Antonio, Texas, 미국, 78209
        • Audie L Murphy Veterans Affairs Hospital
    • Virginia
      • Fredericksburg, Virginia, 미국, 22401
        • Fredericksburg Oncology Inc
    • Washington
      • Bellingham, Washington, 미국, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Bremerton, Washington, 미국, 98310
        • Harrison HealthPartners Hematology and Oncology-Bremerton
      • Kennewick, Washington, 미국, 99336
        • Kadlec Clinic Hematology and Oncology
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      • Seattle, Washington, 미국, 98104
        • Harborview Medical Center
      • Seattle, Washington, 미국, 98104
        • Minor and James Medical PLLC
      • Seattle, Washington, 미국, 98112
        • Group Health Cooperative-Seattle
      • Seattle, Washington, 미국, 98122-4307
        • Swedish Medical Center-First Hill
      • Seattle, Washington, 미국, 98122
        • The Polyclinic
      • Seattle, Washington, 미국, 98112
        • Group Health Cooperative of Puget Sound Oncology Consortium
      • Spokane, Washington, 미국, 99202
        • Cancer Care Northwest - Spokane South
      • Wenatchee, Washington, 미국, 98801
        • Wenatchee Valley Hospital and Clinics
    • West Virginia
      • Charleston, West Virginia, 미국, 25304
        • West Virginia University Charleston
    • Wisconsin
      • Chippewa Falls, Wisconsin, 미국, 54729
        • Marshfield Clinic-Chippewa Center
      • Eau Claire, Wisconsin, 미국, 54701
        • Marshfield Clinic Cancer Center at Sacred Heart
      • Eau Claire, Wisconsin, 미국, 54701
        • Sacred Heart Hospital
      • Marshfield, Wisconsin, 미국, 54449
        • Marshfield Clinic
      • Marshfield, Wisconsin, 미국, 54449
        • Saint Joseph's Hospital
      • Minocqua, Wisconsin, 미국, 54548
        • Marshfield Clinic-Minocqua Center
      • Rhinelander, Wisconsin, 미국, 54501
        • Marshfield Clinic at James Beck Cancer Center
      • Rice Lake, Wisconsin, 미국, 54868
        • Marshfield Clinic-Rice Lake Center
      • Stevens Point, Wisconsin, 미국, 54481
        • Saint Michael's Hospital
      • Wausau, Wisconsin, 미국, 54401
        • Marshfield Clinic-Wausau Center
      • Weston, Wisconsin, 미국, 54476
        • Diagnostic and Treatment Center
      • Weston, Wisconsin, 미국, 54476
        • Marshfield Clinic - Weston Center
      • Wisconsin Rapids, Wisconsin, 미국, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
    • Wyoming
      • Sheridan, Wyoming, 미국, 82801
        • Welch Cancer Center
  • 캐나다
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 4N2
        • Tom Baker Cancer Centre
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
        • BCCA-Vancouver Cancer Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • REGISTRATION # 1
  • Patient must have a biopsy proven diagnosis of gastrointestinal stromal tumor (GIST) that is distantly metastatic or unresectable; patients must be determined to be unresectable for cure
  • Patient may have measurable and/or non-measurable disease; computed tomography (CT) or magnetic resonance imaging (MRI) used for measurable disease must have been completed within 28 days prior to registration; CT or MRI used for non-measurable disease must have been completed within 42 days prior to registration; PET scans are not sufficient for disease assessment; all disease must be assessed and documented on the Baseline Tumor Assessment Form
  • CT/MRI scans must be performed and submitted for central review; archived tissue must be submitted as outlined
  • Institutions must seek additional patient consent for PET scans as outlined; if patient consents to the submission of PET scans, the patient must also be registered to Registration #2
  • Patient must not have known brain metastasis
  • Patient must have a Zubrod performance status of 0 - 3
  • Patient must have resolution of transient toxicities from any prior chemotherapy, radiation therapy or surgery to =< grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
  • Patient may have previously received traditional chemotherapeutic agents in any setting, provided at least 28 days have elapsed since completing chemotherapy and they have recovered to =< grade 1 from all drug-induced toxicities

  • Patient must not have received prior treatment with bevacizumab or other agents targeting VEGF, VEGFR, or PDGFR for advanced disease; those agents may have been used in the adjuvant setting if the patient did not recur for at least 12 months following the completion of treatment; patients may be receiving imatinib for advanced disease prior to registration provided they meet ALL of the following criteria:

    • Patient must not have received more than 30 days of imatinib treatment prior to registration
    • Patients have not been restaged; (baseline disease assessments prior to initiation of imatinib must fulfill requirements)
    • Patients must have no clinical signs of progression
  • Prior radiotherapy is allowed, provided at least 28 days have elapsed since the last treatment and there is evidence of progressive disease within the radiation field or disease outside the radiation field
  • Patient must not have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, or anticipation of need for major surgical procedure during the course of the study; no fine needle aspirations or core biopsies are allowed within 7 days prior to registration; no procedure to place a port-a-cath is allowed within 7 days prior to registration
  • Patient must have a total bilirubin =< 2.0 x institutional upper limit of normal (IULN), obtained within 28 days prior to registration
  • Patients without liver involvement must have serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2.5 x IULN, obtained within 28 days prior to registration; patients with liver involvement must have SGOT or SGPT =< 5 x IULN
  • Patient must have adequate renal function as defined by a serum creatinine =< 1.5 x IULN obtained within 28 days prior to registration
  • Patient must have urine protein/creatinine ratio (UPC) < 1; this result must be obtained within 28 days prior to registration
  • Patient must have an absolute neutrophil count (ANC) >= 1,000/mcl obtained within 28 days prior to registration
  • Patient must have a platelet count >= 100,000/mcl obtained within 28 days prior to registration
  • Patient must have hemoglobin >= 9 gm/dl (this may be achieved by transfusion if needed) obtained within 28 days prior to registration
  • Patient must have an international normalized ratio (INR) =< 1.5, obtained within 28 days prior to registration
  • Patient must have a partial thromboplastin time (PTT) =< IULN, obtained within 28 days prior to registration
  • Patient must not be taking therapeutic doses of Coumadin (warfarin) as anticoagulation at the time of registration; patients requiring therapeutic anticoagulation may use low-molecular weight heparin (e.g., Lovenox) or other agents, and mini-dose Coumadin (1 mg PO QD) as prophylaxis is allowed
  • Patient must not have had a cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction or unstable angina within 6 months prior to registration; patient must not have serious cardiac arrhythmia requiring medication, New York Heart Association (NYHA) class II or greater congestive heart failure, or clinically significant peripheral vascular disease
  • Patient must not have had an abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to registration
  • Patient must not plan to use other investigational agents while on protocol treatment
  • Patient must have no contraindication to oral medications (e.g., severe dysphagia); patients with gastrostomy (G)- or jejunostomy (J)- tubes are eligible
  • Patient must not have blood pressure > 160/90; patients with a history of hypertension must be on a stable regimen of anti-hypertensive therapy
  • Patient must not have a serious, non-healing wound, ulcer, or bone fracture
  • Patient must not be pregnant or nursing; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout protocol treatment and for up to 6 months following discontinuation of study drugs
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
  • If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day; in calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28
  • All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • At the time of patient registration, the treating institution's name and identification (ID) number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base
  • REGISTRATION #2 - PET SUBSTUDY:
  • Patient must have been registered to the main study
  • Patient must have consented to the submission of PET scans

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)
Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
다른: 실험실 바이오마커 분석
상관 연구
다른: 약리학적 연구
상관 연구
생물학적: 베바시주맙
주어진 IV
다른 이름들:
  • 아바스틴
  • 안티-VEGF
  • 항-VEGF 인간화 단클론항체
  • 항-VEGF rhuMAb
  • 베바시주맙 바이오시밀러 BEVZ92
  • 베바시주맙 바이오시밀러 BI 695502
  • 면역글로불린 G1(Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF 경쇄, 이합체
  • 재조합 인간화 항-VEGF 단클론 항체
  • rhuMab-VEGF
의약품: 이마티닙 메실레이트
주어진 PO
다른 이름들:
  • 글리벡
  • CGP 57148
  • CGP57148B
  • 성병 571
  • STI-571
  • STI571
활성 비교기: Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)
Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
다른: 실험실 바이오마커 분석
상관 연구
다른: 약리학적 연구
상관 연구
의약품: 이마티닙 메실레이트
주어진 PO
다른 이름들:
  • 글리벡
  • CGP 57148
  • CGP57148B
  • 성병 571
  • STI-571
  • STI571

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression Free Survival
기간: Up to 7 years
From date of registration (defined as date of randomization) to date of first observation of progressive disease, death due to any cause or symptomatic deterioration. Patients last known to be alive and progression free are censored at last date of contact. Progression is defined as one or more of the following: 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy), provided at least one target lesion does NOT demonstrate uniform hypoattenuation over > 90% of maximal cross sectional area; unequivocal progression of non-measurable disease; appearance of new lesion/site that is not uniformly hypoattenuating; a hyperattenuating region within a previously cystic/uniformly hypoattenuating lesion will be considered progressive disease if hyperattenuating region is either >= 1 cm in longest diameter or round/oval and forms acute margins with border of target lesion; death due to disease.
Up to 7 years

2차 결과 측정

결과 측정
측정값 설명
기간
Response Rate
기간: Up to 7 years
Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.
Up to 7 years
Overall Survival
기간: up to 7 years
From date of registration (defined as date of randomization) to date of death due to any cause. Patients last known to be alive are censored at last date of contact. Note: median was not reached in the Imatinib arm due to limited follow-up data.
up to 7 years
Central-review Based Progression-free Survival (CRb-PFS)
기간: up to 7 years
From date of registration (defined as date of randomization) to date of first documentation of one of the following events: death; first documentation of progression based on central review of the appropriate computed tomography (CT) or magnetic resonance imaging (MRI) scans; development of new lesions or disease not identified on CT or MRI; or symptomatic deterioration. Patients not experiencing any of these events will be censored at last date of contact.
up to 7 years
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
기간: Up to 7 years
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Up to 7 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

National Cancer Institute (NCI)

수사관

  • 수석 연구원: Charles Blanke, Southwest Oncology Group

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 4월 1일

기본 완료 (실제)

2015년 7월 1일

연구 완료 (실제)

2015년 7월 1일

연구 등록 날짜

최초 제출

2006년 5월 10일

QC 기준을 충족하는 최초 제출

2006년 5월 10일

처음 게시됨 (추정)

2006년 5월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 9월 14일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 8월 15일

마지막으로 확인됨

2017년 8월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NCI-2009-00776 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • U10CA032102 (미국 NIH 보조금/계약)
  • U10CA180888 (미국 NIH 보조금/계약)
  • CDR0000482236
  • S0502 (CTEP)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

실험실 바이오마커 분석에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Canada

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다